CRISPR Therapeutics AG (CRSP)
$57.62-$1.75 (-2.95%) Today
James R. Kasinger - Officer
Samarth Kulkarni - Officer
Raju Prasad - OfficerNaimish Patel - OfficerRaju Prasad - OfficerRaju Prasad - OfficerJames R. Kasinger - OfficerCrispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 13 | 188,500 | |
| Bona-fide gift | 1 | 750 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
54 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Raju Prasad - Officer | Gift | Common Shares | 750 | $0.00 | - | |
| Simeon George | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
 Ali Behbahani | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
 Maria Fardis | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Harold Edward Fleming | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| John Greene | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Katherine A. High | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Sandesh Mahatme | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Briggs Morrison | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Christian Rommel | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| Douglas A. Treco | Grant or award | Stock Option (Right to Buy) | 13,000 | $0.00 | - | |
| James R. Kasinger - Officer | Grant or award | Restricted Stock Units | 17,000 | $0.00 | - | |
| Naimish Patel - Officer | Grant or award | Restricted Stock Units | 22,000 | $0.00 | - | |
| Raju Prasad - Officer | Grant or award | Restricted Stock Units | 19,500 | $0.00 | - | |
| Naimish Patel - Officer | Option exercise | Common Shares | 10,000 | - | - | |
| Naimish Patel - Officer | Open-market sale | Common Shares | 3,786 | $55.62 | $211K | |
| Naimish Patel - Officer | Option exercise | Restricted Stock Units | 10,000 | - | - | |
| James R. Kasinger - Officer | Option exercise | Common Shares | 6,250 | - | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 3,182 | $46.78 | $149K | |
| James R. Kasinger - Officer | Grant or award | Stock Option (Right to Buy) | 38,499 | $0.00 | - | |
| James R. Kasinger - Officer | Grant or award | Restricted Stock Units | 25,000 | $0.00 | - | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 6,250 | - | - | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 19,687 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 10,020 | $46.78 | $469K | |
| Samarth Kulkarni - Officer | Grant or award | Stock Option (Right to Buy) | 114,249 | $0.00 | - | |
| Samarth Kulkarni - Officer | Grant or award | Restricted Stock Units | 81,875 | $0.00 | - | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 19,687 | - | - | |
| Raju Prasad - Officer | Option exercise | Common Shares | 6,250 | - | - | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 3,708 | $46.78 | $173K | |
| Raju Prasad - Officer | Grant or award | Stock Option (Right to Buy) | 38,499 | $0.00 | - | |
| Raju Prasad - Officer | Grant or award | Restricted Stock Units | 27,500 | $0.00 | - | |
| Raju Prasad - Officer | Option exercise | Restricted Stock Units | 6,250 | - | - | |
| Naimish Patel - Officer | Grant or award | Stock Option (Right to Buy) | 38,499 | $0.00 | - | |
| Naimish Patel - Officer | Grant or award | Restricted Stock Units | 30,000 | $0.00 | - | |
| Naimish Patel - Officer | Option exercise | Common Shares | 8,125 | - | - | |
| Naimish Patel - Officer | Open-market sale | Common Shares | 3,150 | $48.26 | $152K | |
| Naimish Patel - Officer | Option exercise | Restricted Stock Units | 8,125 | - | - | |
| Raju Prasad - Officer | Option exercise | Common Shares | 10,000 | - | - | |
| Raju Prasad - Officer | Option exercise | Common Shares | 6,875 | - | - | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 5,848 | $48.26 | $282K | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 4,021 | $48.26 | $194K | |
| Raju Prasad - Officer | Gift | Common Shares | 750 | $0.00 | - | |
| Raju Prasad - Officer | Option exercise | Restricted Stock Units | 10,000 | - | - | |
| Raju Prasad - Officer | Option exercise | Restricted Stock Units | 6,875 | - | - | |
| James R. Kasinger - Officer | Option exercise | Common Shares | 6,875 | - | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 3,450 | $48.26 | $166K | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 6,875 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 10,349 | $48.26 | $499K | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 20,625 | - | - | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 20,625 | - | - | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 5,500 | - | - | |
| James R. Kasinger - Officer | Option exercise | Common Shares | 5,500 | - | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 2,800 | $52.80 | $148K | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 19,250 | - | - | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 19,250 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 9,798 | $52.80 | $517K | |
| Samarth Kulkarni - Officer | Option exercise | Common Shares | 13,250 | - | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 6,967 | $52.58 | $366K | |
| Samarth Kulkarni - Officer | Option exercise | Restricted Stock Units | 13,250 | - | - | |
| James R. Kasinger - Officer | Option exercise | Common Shares | 3,825 | - | - | |
| James R. Kasinger - Officer | Open-market sale | Common Shares | 2,112 | $52.58 | $111K | |
| James R. Kasinger - Officer | Option exercise | Restricted Stock Units | 3,825 | - | - | |
| Naimish Patel - Officer | Open-market purchase | Common Shares | 1,508 | $32.96 | $50K | |
| Raju Prasad - Officer | Option exercise | Common Shares | 34,972 | $45.15 | $1.58M | |
| Raju Prasad - Officer | Open-market sale | Common Shares | 34,972 | $60.19 | $2.10M | |
| Raju Prasad - Officer | Option exercise | Stock Option (Right to Buy) | 34,972 | $0.00 | - | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 21,433 | $51.61 | $1.11M | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 8,567 | $52.10 | $446K | |
| Samarth Kulkarni - Officer | Open-market sale | Common Shares | 60,000 | $60.23 | $3.61M |
CRISPR Therapeutics AG (CRSP) had 14 insider filings in the last 90 days, with the most recent on 2026-08-11. The full record for CRSP runs to 54 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CRSP were filed in the last 90 days. 5 purchases are on record for this company.
No insider sales of CRSP were filed in the last 90 days. 32 sales are on record for this company.
This page tracks CRSP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CRSP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
